

accompanying Remarks. To the extent required, Applicants request that the Examiner reconsider and again examine, or otherwise favorably act upon, the subject application in light thereof.

AMENDMENT

In the Specification:

On page 1, line 18, after the term "Figure 5", please insert --; See e.g., SEQ ID NO: 1--.

After page 22 of the specification, please insert the enclosed 3 pages entitled "Sequence Listing" as pages 23 - 25, and renumber pages 23 – 34 as pages 26 – 37, respectively. A sequence listing has been submitted with the human tau protein sequence from Goedert et al. (1989) listed. This material is the same material that was incorporated by reference and is not new material. A signed Declaration has been submitted stating that this is the same material that was incorporated by reference.

In the Claims:

Please rewrite claim 14 as follows:

14. (Amended) A method of determining axonal damage in the human central nervous system, said method comprising the steps:
(a) obtaining a sample of cerebrospinal fluid from said human central nervous system;